BAM15: what the research shows

  • By Reed Calder
  • Last reviewed Nov 16, 2026
  • 36 studies and official documents checked

In short

BAM15 is a small molecule, not a peptide: a “mitochondrial uncoupler” that lets the cell’s energy factories burn fuel without making as much usable energy. It was found in 2014 by screening a chemical library for uncouplers that spare the cell’s outer membrane (Kenwood et al., 2014).

In mice it cut body fat and improved blood sugar. In one study, 5 weeks of BAM15 mixed into the food of male mice on a Western diet left them 15% lighter, almost all of it fat, eating the same amount (Alexopoulos et al., 2020). We found no study that gave BAM15 to people, and no registered trial.

The lab and animal record also shows limits. Blood urea nitrogen was 22% higher in that first study, though still in the normal range. Female diabetic mice ended with less lean mass as well as less fat. A four-pig imaging study stopped one infusion for severe cardiac dysfunction. Roundworms lived 8% shorter on a low dose and 14% longer on a higher one. In human sperm in a dish, BAM15 lowered motility in one study and improved quality after thawing in another. There is no FDA application or drug listing for it, and the 2026 WADA list names it among prohibited AMPK activators.

EvidenceCellAnimalHumanmouse obesity and diabetes studies; no study in people

You’ll often read that BAM15 is a “fat-burning peptide” with minimal side effects that leaves food intake and muscle alone, and that it is well tolerated. This page covers what BAM15 is, what was studied in mice, other animals and cells, the usual claims checked, what the studies used, side effects, where it stands with the FDA and in sport, and what’s still unknown.

Names and forms you’ll see

The names for BAM15 and its relatives
Name What it is Studied in people?
BAM15, BAM-15, BAM 15 The small molecule: 5-N,6-N-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine, formula C16H10F2N6O, 340.29 g/mol (PubChem CID 565708) We found no study
“BAM15 peptide” A search phrase and product label. BAM15 is not a chain of amino acids (PubChem) See the first row
A different “BAM15” An unrelated peptide with the same abbreviation, used as a receptor agonist in pain-receptor research (Kunapuli et al., 2006). Not covered here Not relevant
SHC517, SHD865, SHM115 Related uncouplers made after BAM15. Their mouse results belong to them, not to BAM15 (Chen et al., 2021; Beretta et al., 2024; Murray et al., 2023) We found no study
“SLU-PP-332 + BAM15” and other sold mixes Product combinations. We found no study of any mix; see SLU-PP-332. The mouse studies of BAM15 with semaglutide and with resmetirom used those drugs, not sold mixes We found no study
Mitochondrial uncoupler, “fat burner” Descriptions of what it does in cells. See below for what that means (Kenwood et al., 2014) See the first row

CAS numbers

A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The registry here is PubChem, because the FDA’s substance registry has no BAM15 record.

BAM15 CAS numbers
Form CAS number Registry record
BAM15 (a small molecule, not a peptide) 210302-17-3 PubChem

What BAM15 is

BAM15 is a small molecule with the formula C16H10F2N6O and a weight of 340.29 g/mol (PubChem CID 565708). It was named in a 2014 paper that screened a chemical library for new mitochondrial uncouplers (Kenwood et al., 2014).

Mitochondria are the cell’s energy factories. Uncouplers like BAM15 carry protons into the mitochondria by a path that skips ATP synthase, the enzyme that makes ATP, so nutrients are burned without the same ATP output (Kenwood et al., 2014). In cultured cells BAM15 gave a higher top rate of mitochondrial respiration than FCCP, an older uncoupler of equal potency, and was less toxic (Kenwood et al., 2014).

The older uncoupler 2,4-dinitrophenol, or DNP, did cause weight loss in people: about 90% of patients taking 300 mg a day lost 2 to 3 pounds a week. But the window between effective and toxic doses was narrow, and the FDA banned it for people in 1938 (Alexopoulos et al., 2020). The 2014 team screened for uncouplers without DNP’s effects on other membranes, which it links to a narrow safety margin (Kenwood et al., 2014). Whether BAM15 has a wider margin in people hasn’t been tested.

BAM15 was first described as leaving the cell’s outer membrane alone (Kenwood et al., 2014). That isn’t true everywhere: in neurons from mollusks it depolarized the outer membrane and suppressed electrical activity, and in isolated rat liver mitochondria an inhibitor of the ADP/ATP carrier partly reversed its effect, so a mitochondrial protein is involved (Firsov et al., 2021).

AMPK is a cell energy sensor. In cultured vascular smooth muscle cells BAM15 raised an AMPK activity marker more than metformin or AICAR did (Tai et al., 2018). We found no study showing that BAM15 binds AMPK directly. The 2026 WADA list names it as an AMPK activator (WADA, 2026); see AICAR and MOTS-c for the others in the same entry. A 2025 side-by-side test of 15 uncouplers concluded that uncouplers “should not be generalized” and each needs to be judged by its own actions (Shah et al., 2025).

What has been studied

We found no study that gave BAM15 to people. Everything below comes from mice, other animals and cells. Most of the mouse work mixed BAM15 into food, so the amounts in the tables are shares of the food, not injections. PubMed lists 75 records that mention BAM15 (searched November 16, 2026); many are laboratory papers that use it as a tool rather than study it as a treatment.

In mice: weight, fat and blood sugar

Studies of BAM15 in mice on weight, fat and blood sugar
Study Model What was used What it found
Alexopoulos et al., 2020 Male C57BL/6J mice: 4 weeks of a Western diet, then 5 weeks of treatment BAM15 at 0.1% of the food by weight The treated group ate the same calories and weighed 15% less, almost entirely fat, with no difference in lean mass. Liver, muscle and heart enzymes were unchanged and creatinine was normal; blood urea nitrogen was 22% higher but within the normal range (5 mice). Insulin clamps showed better insulin sensitivity in several tissues. Three authors have a financial interest in Continuum Biosciences, a company that develops uncouplers
Axelrod et al., 2020 Male diet-induced obese mice, 10 weeks old, 3 weeks BAM15 at 0.1% of a high-fat diet (about 85 mg/kg a day eaten) Treated mice resisted weight gain and had better body composition and glucose control independent of weight loss; a calorie-restricted group matched for weight loss served as a comparison. One author reports equity in Continuum Biosciences
Chen et al., 2023 Male db/db mice (severe diabetes, obesity and fatty liver), 4 weeks from age 5 weeks BAM15 at 0.1% or 0.2% of the food, against about 50% calorie restriction At 0.2%, weight fell about as much as with calorie restriction and fasting glucose and glucose tolerance returned to the level of lean mice. At 0.1%, weight did not change but glucose tolerance partly improved. Glucagon and liver and blood triglycerides fell
Chen et al., 2024 Female db/db mice BAM15 at 0.2% of the food, against about 60% calorie restriction, semaglutide, rosiglitazone and niclosamide ethanolamine BAM15 and calorie restriction lowered weight and liver fat more than the other three; BAM15, semaglutide and rosiglitazone improved glucose tolerance more than calorie restriction. Both BAM15 and calorie restriction left the mice with less fat mass and less fat-free mass than untreated db/db mice. Two authors report equity in uncoupler companies
Dantas et al., 2022 Obese male mice aged 80 weeks, 10 weeks BAM15 at 0.1% of a high-fat diet Body weight 42.3 g against 54.0 g. Muscle as a share of body weight rose from 52.7% to 59.4%, grip strength from 91.1 to 124.9 g and distance moved from 347 to 433 m. A higher percentage is not the same as more muscle; total glucose tolerance did not improve significantly, and one mouse died during treatment with the cause unresolved
Shah et al., 2025 Male db/db mice, 4 weeks BAM15 at 0.15% or 0.2% of the food, against four other uncouplers and 35% calorie restriction Among the five uncouplers tested in mice, BAM15 had the best overall effects on weight, glucose control and liver fat; at 0.2% weight, fat pads, glucose tolerance and liver fat improved significantly. The authors disclose commercial interests
Chen et al., 2024 (semaglutide) Mice on a Western diet BAM15 alone, low or high dose semaglutide alone, or each semaglutide dose with BAM15 Adding BAM15 to either semaglutide dose lowered body fat and liver triglycerides in a way no single drug did, and high-dose semaglutide with BAM15 improved glucose handling most. Some comparisons with a single drug were not significant, and the study did not show fewer semaglutide side effects
Zhou et al., 2024 Male mice with fatty liver disease after 38 weeks on a GAN diet, 8 weeks of treatment BAM15, resmetirom (an approved fatty-liver drug) or both, in the food, with matched intake The pair beat either alone for energy expenditure, liver fat, glucose control and a fatty-liver activity score. Body fat fell mainly with BAM15; liver enzymes and cholesterol improved mainly with resmetirom. No treatment changed liver fibrosis. A 2025 correction concerns a drawing of resmetirom’s structure (PubMed 39533750)

EvidenceCellAnimalHumanmice only; some results differ by sex, diet and what the comparison group ate

In mice and cells: other conditions

Studies of BAM15 in mouse and cell models of other conditions
Study Model What was used What it found
Kenwood et al., 2014 Mice, and cultured cells BAM15 given to mice before a kidney blood-flow injury Protected mice from acute kidney ischemia-reperfusion injury in a dose-dependent way
Tsuji et al., 2023 Mice with sepsis from cecal ligation and puncture, given fluids and antibiotics BAM15 injected at 0, 6 or 12 hours after surgery Fewer deaths, even when given at 12 hours, with less kidney damage and spleen cell death. Mitochondrial DNA in blood and urine fell when it was given at 0 or 6 hours
Gao et al., 2022 Human acute myeloid leukemia cells, normal cells and mice with leukemia BAM15 alone and with the drug cytarabine Slowed leukemia cell growth and triggered cell death with less toxicity to normal cells; slowed progression and lengthened survival in mice; added to the effect of cytarabine
Zunica et al., 2021 Human and mouse breast cancer cells; mice with mammary tumors, lean or on a high-fat diet BAM15 on cells and in the mice Slowed cell growth and migration. In mice it slowed tumor growth compared with untreated mice and with calorie-restricted mice of the same weight. Tumors were not eradicated
Ma et al., 2025 ApoE-null mice on a Western diet; macrophage cells BAM15 by mouth Smaller artery plaques, better blood fats and lower liver enzymes. Computer docking results are predictions, not measured binding

EvidenceCellAnimalHumanmouse and cell results; none tested in people

In other animals

Studies of BAM15 in other animals
Study Model What was used What it found
Alpert et al., 2020 Four pigs, in a heart imaging study BAM15 infused into a heart artery; 1 mg/min over 25 minutes in one test, then 1.2 mg/min The tracer level fell in the infused area, a sign of lower mitochondrial voltage (up to 10 mV), then recovered. A second infusion at 1.2 mg/min was stopped after 10 minutes because of cardiac dysfunction. No control infusions were done, so the solvents (DMSO and polysorbate 80) could be involved
Cho et al., 2022 Roundworms (C. elegans) BAM15 at 10 or 50 µM in the culture At 50 µM, aged worms kept their touch response and short-term memory and lived 14% longer on average (28% in a mutant strain). At 10 µM mean lifespan was 8% shorter
Taylor et al., 2024 Fruit flies BAM15 in normal or high-fat food Male flies lived about 9% longer on a normal diet and about 24% longer on a high-fat diet. The lifespan effect was not seen in females
Wang et al., 2026 Golden apple snails, an invasive pest BAM15 in the water for 72 hours It killed the snails: the dose that kills half was 0.4564 mg/L for adults and 0.1142 mg/L for juveniles, with oxidative stress and tissue damage. The authors propose it as a snail killer

EvidenceCellAnimalHumana pig imaging pilot, worms, flies and snails; not mammal efficacy studies

In human cells

Studies of BAM15 in human cells
Study Model What was used What it found
Skinner et al., 2023 Human sperm in a dish BAM15, and the drug niclosamide ethanolamine BAM15 lowered the mitochondrial voltage and the share of sperm swimming forward, without lowering ATP. Sperm could rely on sugar breakdown for energy. Not a contraceptive or fertility trial
Chen et al., 2026 Human sperm frozen and thawed in a dish BAM15 added at graded amounts to a standard freezing protocol After thawing, more sperm were moving and alive, with less DNA fragmentation and less oxidative damage than untreated sperm. A different setting from the first study, not a failed copy of it
Gao et al., 2022 Human leukemia cells BAM15 See the table above: effects on leukemia cells, with less toxicity to normal cells in the same study

EvidenceCellAnimalHumancells in a dish; no one was given BAM15

The usual claims, checked

Common BAM15 claims vs the studies
Claim Verdict What the studies found
BAM15 is a peptide Contradicted No. It is a small molecule, C16H10F2N6O (PubChem)
It burns fat Untested We found no study in people. In male mice on a Western diet it cut body weight 15% and the loss was almost all fat; in diabetic mice it lowered fat and liver fat (Alexopoulos et al., 2020; Chen et al., 2023; Chen et al., 2024)
It reverses obesity without changing food intake or lean mass Mixed In male diet-fed mice, food intake and lean mass did not differ. In female diabetic mice, 0.2% BAM15 left less fat-free mass than in untreated mice, and the aged-mouse muscle gain was a rise in percentage of body weight (Alexopoulos et al., 2020; Chen et al., 2024; Dantas et al., 2022)
It improves insulin sensitivity and blood sugar Untested In mice it lowered fasting glucose and improved glucose tolerance, in one study to the level of lean mice. We found no study in people (Alexopoulos et al., 2020; Chen et al., 2023)
It builds or protects muscle Mixed Aged obese male mice had more grip strength and a higher muscle percentage, with one unexplained death; female diabetic mice lost fat-free mass. No study in people (Dantas et al., 2022; Chen et al., 2024)
It is safe for people Untested We found no study in people, so there is no human safety evidence either way. The animal and lab findings are under side effects below
It has no side effects in animals Contradicted The first mouse study reported no change in body temperature or most blood markers, but blood urea nitrogen was 22% higher. Other animal work found a stopped pig infusion, a shorter worm lifespan at a low dose and kills in snails (Alexopoulos et al., 2020; Alpert et al., 2020; Cho et al., 2022; Wang et al., 2026)
It is well tolerated with minimal adverse effects Untested That wording appears in a review that ranks first on Google; its safety section cites a 2020 mouse study (Xiong et al., 2023; Axelrod et al., 2020). The studies above add the findings listed under side effects, and none is in people
It treats sepsis, cancer, kidney injury or heart disease Untested Mouse and cell results only: fewer deaths in mice with sepsis, slower leukemia and breast tumors, less kidney injury and smaller artery plaques. No study in people (Tsuji et al., 2023; Gao et al., 2022; Zunica et al., 2021; Kenwood et al., 2014; Ma et al., 2025)
It extends lifespan Mixed Mixed in simple animals: worms lived 14% longer at 50 µM and 8% shorter at 10 µM; male flies lived longer, females did not. We found no lifespan study in mammals (Cho et al., 2022; Taylor et al., 2024)
It is a direct AMPK activator Mixed AMPK activity markers rose in cells given BAM15, but we found no study showing it binds AMPK, and uncouplers act through the mitochondria (Tai et al., 2018; Kenwood et al., 2014)
It spares the cell’s outer membrane, so it is selective Mixed True in the cells first tested. In mollusk neurons it depolarized the outer membrane, and the authors of a 15-uncoupler comparison say each uncoupler needs its own evaluation (Kenwood et al., 2014; Firsov et al., 2021; Shah et al., 2025)
It works when taken by mouth Untested In mice, yes: 67% of an oral dose was bioavailable. We found no study in people (Alexopoulos et al., 2020)
It has been tested in people Contradicted We found none. ClinicalTrials.gov returns one record for BAM15, a COVID antibody trial that names a different drug, and PubMed lists no study of BAM15 in volunteers (ClinicalTrials.gov search)
BAM15 is a safer version of DNP Untested Untested in people. DNP’s window between effective and toxic doses was narrow; the 2014 team screened for uncouplers that avoid DNP’s effects on other membranes (Kenwood et al., 2014; Alexopoulos et al., 2020)
BAM15 is an FDA-approved drug Contradicted No. We found no Drugs@FDA application and no drug listing (openFDA; openFDA NDC)
Research-grade BAM15 contains the amount on the label Untested We found no published analysis of BAM15 products sold online, so the claim is untested
BAM15 is banned in sport Supported Yes. The 2026 WADA list names BAM15 among AMPK activators, prohibited at all times (WADA, 2026)

Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.

What the studies used

Amounts used in the BAM15 studies
Study What was tested Amount and route
Alexopoulos et al., 2020 Obesity reversal in male mice 0.1% of a Western diet for 5 weeks; blood levels 5 to 10 µM overnight
Alexopoulos et al., 2020 Absorption in mice 67% bioavailable by mouth, peak 8.2 µM, half-life 1.7 hours; single oral doses up to 200 mg/kg did not change body temperature. Doses were not raised further because it was hard to dissolve and the mice showed brief lethargy that could not be separated from the paste used to deliver it
Axelrod et al., 2020 Obese male mice 0.1% of a high-fat diet for 3 weeks, about 85 mg/kg a day eaten, peak blood level about 5 µM
Chen et al., 2023 Male db/db mice 0.1% and 0.2% of the food for 4 weeks
Shah et al., 2025 Male db/db mice 0.15% and 0.2% of the food for 4 weeks
Dantas et al., 2022 Aged obese male mice 0.1% of a high-fat diet for 10 weeks
Alpert et al., 2020 Four pigs, heart imaging 1 mg/min over 25 minutes into a heart artery; a second infusion at 1.2 mg/min was stopped after 10 minutes (37 mg in total in that pig)
Cho et al., 2022 Roundworms 10 µM and 50 µM in the culture
Wang et al., 2026 Golden apple snails 72-hour LC50 of 0.4564 mg/L for adults, 0.3352 mg/L for subadults and 0.1142 mg/L for juveniles

Every amount above is an animal or laboratory amount. We found no human dose, and a share of mouse food does not convert to a number for a person. Nothing here is a dosing recommendation, and we don’t repeat schedules from seller pages.

Side effects and safety

  • In people. We found no study that gave BAM15 to people, so there are no human side-effect data, and a missing report of harm isn’t evidence of safety.
  • In the first mouse obesity study. The abstract says BAM15 did not change body temperature or markers of toxicity. The results say blood urea nitrogen was 22% higher, within the normal range for that mouse strain, while liver, muscle and heart enzymes and creatinine were unchanged. In a dose test, brief lethargy appeared at the top single dose and could not be separated from the paste used to deliver it (Alexopoulos et al., 2020).
  • Lean mass. In female diabetic mice, BAM15 at 0.2% left less fat mass and less fat-free mass than untreated db/db mice (Chen et al., 2024). In the aged-mouse study, muscle rose as a share of body weight, and one mouse died during treatment with the cause unresolved (Dantas et al., 2022).
  • The heart. In a four-pig imaging pilot, a second infusion into a heart artery was stopped after 10 minutes because of cardiac dysfunction. The authors did not run control infusions, so the solvents could be involved (Alpert et al., 2020).
  • Other animals. At a low dose, worms lived 8% shorter on average; in flies the lifespan gain was seen in males only; in snails BAM15 killed at fractions of a milligram per liter, with tissue damage (Cho et al., 2022; Taylor et al., 2024; Wang et al., 2026).
  • Sperm. In a dish, BAM15 lowered the share of human sperm swimming forward without lowering ATP. In a separate study of frozen sperm it improved quality after thawing (Skinner et al., 2023; Chen et al., 2026). Neither tested fertility.
  • Cancer studies. In the leukemia work BAM15 was less toxic to normal cells than to leukemia cells; that is a comparison in a dish and in mice, not a safety test in people (Gao et al., 2022). In the breast cancer study tumors were slowed, not eradicated (Zunica et al., 2021).
  • Who paid and who gains. Three authors of the first mouse study have a financial interest in Continuum Biosciences, and two authors of the female-mouse study report equity in uncoupler companies (Alexopoulos et al., 2020; Chen et al., 2024).
  • Not known. Long-term safety, safety in pregnancy, drug interactions, the effect on the heart and kidneys in people, and what the body does with BAM15 in people. Side effects people report online aren’t covered here; they come from users, not studies.

Legal and approval status

  • Not approved. We found no Drugs@FDA application and no drug listing for BAM15 (openFDA; openFDA NDC).
  • Compounding. BAM15 isn’t named in the FDA’s list of bulk substances nominated for compounding under section 503A, updated May 14, 2026, or on the FDA’s page of bulk substances that may present significant safety risks, current as of April 22, 2026 (FDA document; FDA page). We did not research whether pharmacies may lawfully compound it.
  • Not in the HHS policy. The October 2026 temporary policy covers six other peptides, not BAM15 (Reuters, 2026).
  • Other countries. We did not check how other countries regulate it.
  • Sport. The World Anti-Doping Agency’s 2026 list, section S4.4.1, names AMP-activated protein kinase activators, including BAM15, AICAR and MOTS-c, prohibited at all times (WADA, 2026).

What to look for if you research it

We don’t name or link sellers. These checks come from the studies and from the FDA:

  • “Peptide.” BAM15 is a small molecule, not a peptide.
  • “Clinical trials” or “human studies.” We found none. The results are from mice, other animals and cells.
  • “Minimal side effects.” Check what the claim cites. The first mouse study had a blood urea nitrogen rise, and later animal work found a stopped pig infusion and lean-mass loss in female diabetic mice.
  • “No effect on food intake or muscle.” That was measured in male mice. Female diabetic mice lost fat-free mass, and a higher muscle percentage is not more muscle.
  • “Dose” and “when to take it.” There is no tested human dose or timing. The mouse amounts are shares of food.
  • “Same as the paper.” The papers used lab material under supervision. We found no analysis of BAM15 sold online, so ask for the test report for the batch.
  • Mixes. A blend with SLU-PP-332 or another compound is its own product, and we found no study of any mix.
  • Competition. The 2026 WADA list names BAM15.

Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite.

Trials under way

We found no BAM15 trial that is recruiting or active, so there is nothing to list on our recruiting or in-progress pages. A ClinicalTrials.gov search for BAM15 on November 16, 2026 returned one record: NCT04634409, a completed COVID-19 antibody trial that names bamlanivimab, a different drug (search). A registry search isn’t proof that no unregistered study exists.

What’s still unknown

  • Whether BAM15 does anything for weight, fat or blood sugar in people; we found no human study.
  • Whether any dose is safe and tolerable in people, and what the safe range is compared with DNP’s narrow one.
  • What repeated dosing does to the kidneys, heart and muscle over months; the longest mouse studies we cite ran 10 weeks.
  • Whether the female-mouse lean-mass loss and the pig heart event happen in people.
  • Whether the lifespan findings in worms and flies mean anything for mammals; we found no mammal lifespan study.
  • How BAM15 affects fertility; the two human-sperm studies in a dish point in opposite directions.
  • What is in BAM15 sold online; we found no analysis.

Retracted and flagged studies

A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.

We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention BAM15. We recheck every month. Last checked Nov 16, 2026.

We found no retracted, withdrawn or flagged studies that mention BAM15.

Studies this page relies on

Status of every study cited on this page
Study Published in Status
Kunapuli et al., 2006 Anal Biochem No retraction or concern
Kenwood et al., 2014 Mol Metab No retraction or concern
Tai et al., 2018 Acta Pharm Sin B No retraction or concern
Alexopoulos et al., 2020 Nat Commun No retraction or concern
Alpert et al., 2020 Front Physiol No retraction or concern
Axelrod et al., 2020 EMBO Mol Med No retraction or concern
Firsov et al., 2021 Bioelectrochemistry No retraction or concern
Chen et al., 2021 Metabolism No retraction or concern
Zunica et al., 2021 Cancer Metab No retraction or concern
Gao et al., 2022 Biochem Pharmacol No retraction or concern
Dantas et al., 2022 J Cachexia Sarcopenia Muscle No retraction or concern
Cho et al., 2022 Metabolites No retraction or concern
Chen et al., 2023 Mol Metab No retraction or concern
Tsuji et al., 2023 J Clin Invest No retraction or concern
Murray et al., 2023 J Med Chem No retraction or concern
Skinner et al., 2023 Biol Reprod No retraction or concern
Chen et al., 2024 Biochim Biophys Acta Mol Basis Dis No retraction or concern
Beretta et al., 2024 Diabetes No retraction or concern
Xiong et al., 2023 Front Endocrinol (Lausanne) No retraction or concern
Chen et al., 2024 Clin Sci (Lond) No retraction or concern
Taylor et al., 2024 Aging Cell No retraction or concern
Zhou et al., 2024 Acta Physiol (Oxf) No retraction or concern
Ma et al., 2025 Sci Rep No retraction or concern
Shah et al., 2025 Mol Metab No retraction or concern
Wang et al., 2026 Molecules No retraction or concern
Chen et al., 2026 Biol Reprod No retraction or concern

Bring your questions to other researchers

Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.

Questions

What is BAM15?

BAM15 is a small-molecule mitochondrial uncoupler: it carries protons into the mitochondria so the cell burns fuel without making as much ATP. It was named in 2014 (Kenwood et al., 2014; PubChem).

Is BAM15 a peptide?

No. It is a small molecule with the formula C16H10F2N6O, not a chain of amino acids (PubChem CID 565708).

What does BAM15 peptide do?

There is no “BAM15 peptide”; BAM15 is a small molecule. In mice it cut body fat and improved blood sugar, and we found no study in people (Alexopoulos et al., 2020; Chen et al., 2023).

Does BAM15 burn fat?

In male mice on a Western diet it cut body weight 15%, almost all fat, with the same food intake. We found no study in people (Alexopoulos et al., 2020).

Is BAM15 safe to take?

Unknown in people: we found no human study. In animals, blood urea nitrogen rose 22% in the first mouse study, a pig infusion was stopped for cardiac dysfunction, and female diabetic mice lost fat-free mass (Alexopoulos et al., 2020; Alpert et al., 2020; Chen et al., 2024).

What are the side effects of BAM15?

We found no human side-effect data. Animal findings include a rise in blood urea nitrogen, brief lethargy at the top single dose that was hard to separate from the delivery paste, a pig infusion stopped for cardiac dysfunction, and lower sperm motility in a dish (Alexopoulos et al., 2020; Alpert et al., 2020; Skinner et al., 2023).

Has BAM15 been tested in humans?

We found no study that gave BAM15 to people and no registered trial; the one registry record for the term is a COVID antibody trial (NCT04634409).

What dose of BAM15 did the studies use?

Only animal and lab amounts: for example 0.1% of mouse food for 5 weeks. There is no human dose. See what the studies used. It is not a dosing recommendation (Alexopoulos et al., 2020).

When should BAM15 be taken?

We found no human study, so there is no tested time of day or schedule. In the mouse studies it was mixed into food that the mice ate at will (Alexopoulos et al., 2020).

How long does BAM15 stay in the body?

In mice the half-life was 1.7 hours in one study and about 3 hours in another; we found no human data (Alexopoulos et al., 2020; Axelrod et al., 2020).

Does BAM15 build or protect muscle?

Aged obese male mice had more grip strength and a higher muscle percentage, with one unexplained death; female diabetic mice lost fat-free mass. We found no study in people (Dantas et al., 2022; Chen et al., 2024).

Is BAM15 FDA-approved?

No. We found no Drugs@FDA application and no drug listing (openFDA; openFDA NDC).

Is BAM15 banned in sport?

Yes. The 2026 WADA list names BAM15 among AMPK activators, prohibited at all times (WADA, 2026).

What is the difference between BAM15 and DNP?

Both are mitochondrial uncouplers. DNP caused weight loss in people but with a narrow window between effective and toxic doses, and the FDA banned it for people in 1938. BAM15 hasn’t been tested in people (Alexopoulos et al., 2020).

What is the difference between BAM15 and SLU-PP-332?

They are different compounds that sellers pair in mixes. See what the research shows on SLU-PP-332. We found no study of the mix.

Does BAM15 affect fertility?

Not tested in people. In a dish, BAM15 lowered human sperm motility in one study and improved quality after thawing in another (Skinner et al., 2023; Chen et al., 2026).

Are there BAM15 clinical trials recruiting?

We found none. A ClinicalTrials.gov search returns one COVID antibody trial that names a different drug (search, November 16, 2026).

Sources

  1. Kenwood BM, et al. Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane. Mol Metab. 2014;3(2):114-23. PubMed 24634817
  2. Firsov AM, et al. Protonophoric action of BAM15 on planar bilayers, liposomes, mitochondria, bacteria and neurons. Bioelectrochemistry. 2021;137:107673. PubMed 32971482
  3. Tai Y, et al. Mitochondrial uncoupler BAM15 inhibits artery constriction and potently activates AMPK in vascular smooth muscle cells. Acta Pharm Sin B. 2018;8(6):909-918. PubMed 30505660
  4. Alexopoulos SJ, et al. Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice. Nat Commun. 2020;11(1):2397. PubMed 32409697
  5. Axelrod CL, et al. BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control. EMBO Mol Med. 2020;12(7):e12088. PubMed 32519812
  6. Chen SY, et al. Targeting negative energy balance with calorie restriction and mitochondrial uncoupling in db/db mice. Mol Metab. 2023;69:101684. PubMed 36731653
  7. Chen SY, et al. Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice. Biochim Biophys Acta Mol Basis Dis. 2024;1870(1):166908. PubMed 37793464
  8. Dantas WS, et al. Mitochondrial uncoupling attenuates sarcopenic obesity by enhancing skeletal muscle mitophagy and quality control. J Cachexia Sarcopenia Muscle. 2022;13(3):1821-1836. PubMed 35304976
  9. Shah DP, et al. Diverse actions of 15 structurally unrelated mitochondrial uncouplers in cells and mice. Mol Metab. 2025;99:102204. PubMed 40639664
  10. Chen SY, et al. Beneficial effects of simultaneously targeting calorie intake and calorie efficiency in diet-induced obese mice. Clin Sci (Lond). 2024;138(4):173-187. PubMed 38315575
  11. Zhou M, et al. Beneficial effects of MGL-3196 and BAM15 combination in a mouse model of fatty liver disease. Acta Physiol (Oxf). 2024;240(10):e14217. PubMed 39152636
  12. Correction to “Beneficial effects of MGL-3196 and BAM15 combination in a mouse model of fatty liver disease.” Acta Physiol (Oxf). 2025;241(1):e14250. PubMed 39533750
  13. Tsuji N, et al. BAM15 treats mouse sepsis and kidney injury, linking mortality, mitochondrial DNA, tubule damage, and neutrophils. J Clin Invest. 2023;133(7):e152401. PubMed 36757801
  14. Gao ZX, et al. The new mitochondrial uncoupler BAM15 induces ROS production for treatment of acute myeloid leukemia. Biochem Pharmacol. 2022;198:114948. PubMed 35192847
  15. Zunica ERM, et al. Breast cancer growth and proliferation is suppressed by the mitochondrial targeted furazano[3,4-b]pyrazine BAM15. Cancer Metab. 2021;9(1):36. PubMed 34627389
  16. Ma M, et al. Combining RNA-seq, molecular docking and experimental verification to explore the mechanism of BAM15 as a potential drug for atherosclerosis. Sci Rep. 2025;15(1):13347. PubMed 40247008
  17. Alpert NM, et al. In-vivo Imaging of Mitochondrial Depolarization of Myocardium With Positron Emission Tomography and a Proton Gradient Uncoupler. Front Physiol. 2020;11:491. PubMed 32499721
  18. Cho I, et al. BAM15 Relieves Neurodegeneration in Aged Caenorhabditis elegans and Extends Lifespan. Metabolites. 2022;12(11):1129. PubMed 36422268
  19. Taylor AL, et al. Restricting bioenergetic efficiency enhances longevity and mitochondrial redox capacity in Drosophila melanogaster. Aging Cell. 2024;23(5):e14107. PubMed 38343281
  20. Wang L, et al. BAM 15 Exerts Molluscicidal Effects on Pomacea canaliculata Through the Induction of Oxidative Stress, Impaired Energy Metabolism, and Tissue Damage. Molecules. 2026;31(2):361. PubMed 41599409
  21. Skinner WM, et al. Mitochondrial uncouplers impair human sperm motility without altering ATP content. Biol Reprod. 2023;109(2):192-203. PubMed 37294625
  22. Chen B, et al. Mitochondrial uncoupler BAM15 attenuates cryopreservation-induced damage in human sperm by stabilizing mitochondrial homeostasis. Biol Reprod. 2026;115(3):777-788. PubMed 42295994
  23. Xiong G, et al. BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases. Front Endocrinol (Lausanne). 2023;14:1252141. PubMed 37900126
  24. Kunapuli P, et al. Identification of small molecule antagonists of the human mas-related gene-X1 receptor. Anal Biochem. 2006;351(1):50-61. PubMed 16510108
  25. Chen SY, et al. Mitochondrial uncoupler SHC517 reverses obesity in mice without affecting food intake. Metabolism. 2021;117:154724. PubMed 33548253
  26. Beretta M, et al. Liver-Selective Imidazolopyrazine Mitochondrial Uncoupler SHD865 Reverses Adiposity and Glucose Intolerance in Mice. Diabetes. 2024;73(3):374-384. PubMed 37870907
  27. Murray JH, et al. Oxadiazolopyridine Derivatives as Efficacious Mitochondrial Uncouplers in the Prevention of Diet-Induced Obesity. J Med Chem. 2023;66(6):3876-3895. PubMed 36882080
  28. ClinicalTrials.gov. Search for BAM15, November 16, 2026: one record, NCT04634409, a COVID-19 antibody trial that names bamlanivimab, not BAM15. Search
  29. World Anti-Doping Agency. 2026 Prohibited List, section S4.4.1 (AMPK activators, including BAM15, AICAR and MOTS-c). WADA document
  30. U.S. Food and Drug Administration. openFDA Drugs@FDA: searches for BAM15 and BAM-15 found no application, November 16, 2026. openFDA
  31. U.S. Food and Drug Administration. openFDA drug listings (NDC): searches for BAM15 and BAM-15 found no listing, November 16, 2026. openFDA NDC
  32. U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding (content current as of April 22, 2026; BAM15 not named). FDA page
  33. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A: categories, updated May 14, 2026 (BAM15 not named). FDA document
  34. Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
  35. National Library of Medicine. PubChem: BAM15 (CID 565708). PubChem
  36. National Library of Medicine. PubChem compound record: BAM15 (a small molecule, not a peptide) (CID 565708). PubChem

Last reviewed Nov 16, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.